Oncology News


Latest News

FDA_drug approval

Tazverik Gets FDA Approval for Epithelioid Sarcoma

The FDA has granted accelerated approval to Tazverik™ (tazemetostat tablets; Epizyme) for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Next post in ASCO GI 2020